|
1) Cohn L, Elias JA, Chupp GL. Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol. 2004; 22: 789-815
|
|
|
|
2) Levine SJ, Wenzel SE. Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes. Ann Intern Med. 2010; 152: 232-7
|
|
|
|
|
|
3) Thorburn AN, Hansbro PM. Harnessing regulatory T cells to suppress asthma: from potential to therapy. Am J Respir Cell Mol Biol. 2010; 43: 511-9
|
|
|
|
|
|
4) Fukuda T, Fukushima Y, Numao T, et al. Role of interleukin-4 and vascular cell adhesion molecule-1 in selective eosinophil migration into the airways in allergic asthma. Am J Respir Cell Mol Biol. 1996; 14: 84-94
|
|
|
|
|
|
5) Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science. 1998; 282: 2258-61
|
|
|
|
|
|
6) Mattes J, Yang M, Siqueira A, et al. IL-13 induces airways hyperreactivity independently of the IL-4R alpha chain in the allergic lung. J Immunol. 2001; 167: 1683-92
|
|
|
|
|
|
7) Hogan SP, Mould A, Kikutani H, et al. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest. 1997; 99: 1329-39
|
|
|
|
|
|
8) Vermeer PD, Harson R, Einwalter LA, et al. Interleukin-9 induces goblet cell hyperplasia during repair of human airway epithelia. Am J Respir Cell Mol Biol. 2003; 28: 286-95
|
|
|
|
|
|
9) Saenz SA, Taylor BC, Artis D. Welcome to the neighborhood: epithelial cell-derived cytokines license innate and adaptive immune responses at mucosal sites. Immunol Rev. 2008; 226: 172-90
|
|
|
|
|
|
10) Coyle AJ, Le Gros G, Bertrand C, et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol. 1995; 13: 54-9
|
|
|
|
|
|
11) Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol. 2001; 107: 963-70
|
|
|
|
|
|
12) Hart PH, Bonder CS, Balogh J, et al. Differential responses of human monocytes and macrophages to IL-4 and IL-13. J Leukoc Biol. 1999; 66: 575-8
|
|
|
|
|
|
13) Wenzel S, Wilbraham D, Fuller R, et al. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007; 370: 1422-31
|
|
|
|
|
|
14) Corren J, Busse W, Meltzer EO, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4R alpha antagonist, in patients with asthma. Am J Respir Crit Care Med. 2010; 181: 788-96
|
|
|
|
|
|
15) Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011; 183: 1007-14
|
|
|
|
|
|
16) Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990; 323: 1033-9
|
|
|
|
|
|
17) Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000; 356: 2144-8
|
|
|
|
|
|
18) Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003; 167: 199-204
|
|
|
|
|
|
19) Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest. 2003; 112: 1029-36
|
|
|
|
|
|
20) Flood-Page P, Swenson C, Faiferman I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007; 176: 1062-71
|
|
|
|
|
|
21) Kips JC, O'Connor BJ, Langley SJ, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003; 167: 1655-9
|
|
|
|
|
|
22) Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360: 973-84
|
|
|
|
|
|
23) Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009; 360: 985-93
|
|
|
|
|
|
24) Howarth PH, Babu KS, Arshad HS, et al. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax. 2005; 60: 1012-8
|
|
|
|
|
|
25) Berry MA, Hargadon B, Shelley M, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med. 2006; 354: 697-708
|
|
|
|
|
|
26) Morjaria JB, Chauhan AJ, Babu KS, et al. The role of a soluble TNF alpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. Thorax. 2008; 63: 584-91
|
|
|
|
|
|
27) Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009; 179: 549-58
|
|
|
|
|
|
28) White B, Leon F, White W, et al. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. Clin Ther. 2009; 31: 728-40
|
|
|
|
|
|
29) Parker JM, Oh CK, Laforce C, et al. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 2011; 11: 14
|
|
|
|
|
|
30) Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute severe asthma. Lancet. 1988; 1: 1129-32
|
|
|
|
|
|
31) Park CS, Lee SM, Chung SW, et al. Interleukin-2 and soluble interleukin-2 receptor in broncho-alveolar lavage fluid from patients with bronchial asthma. Chest. 1994; 106: 400-6
|
|
|
|
|
|
32) Busse WW, Israel E, Nelson HS, et al. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med. 2008; 178: 1002-8
|
|
|
|
|
|
33) Bryan SA, O'Connor BJ, Matti S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000; 356: 2149-53
|
|
|
|
|
|
34) Simon HU, Seelbach H, Ehmann R, et al. Clinical and immunological effects of low-dose IFN-alpha treatment in patients with corticosteroid-resistant asthma. Allergy. 2003; 58: 1250-5
|
|
|
|
|
|
35) Kroegel C, Bergmann N, Foerster M, et al. Interferon-alpha con-1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose. Respiration. 2006; 73: 566-70
|
|
|
|
|